sucrosomial iron
Small moleculeexperimental
Sucrosomial iron is a new oral iron preparation containing ferric pyrophosphate covered by phospholipids plus sucrose ester of fatty acid matrix. This allows the molecule to be absorbed in the gastrointestinal tract by trans-cellular, para-cellular and M-cells independently of hepcidin and due to gastro-resistant properties, it does not cause the side effects such as gastric irritation which is commonly associated to oral iron. — Wikipedia
Clinical trial activity
14 trials · 20 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
3
Phase 4
5
Earliest trial started Apr 1, 2015 (NCT02916654)
Timeline
Indications
Approved for
Studied for
- Anemia · Phase 4
- Anemia, Iron-Deficiency · Phase 3
- Brain Injuries, Traumatic · Early Phase 1
- Colitis, Ulcerative · Phase 3
- Consciousness Disorders · Early Phase 1
- Heart Failure · Phase 4
- Heart Failure, Diastolic · Phase 3
- Heart Failure, Systolic · Phase 4
- Hypertrophy, Left Ventricular · Phase 4
- Inflammatory Bowel Diseases · Phase 3
- Iron Deficiencies · Phase 4
- Vitamin D Deficiency · Phase 4
Mechanism of action
- IronSupplementation
Iron supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSucrosomial iron ↗
Also known as
- sucrosomial iron
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07287371 | Phase 4 | Dec 31, 2025 | Pharmanutra s.r.l., University of Rochester |
| NCT07038330 | Phase 4 | Jun 23, 2025 | Cardiochirurgia E.H., European Hospital |
| NCT06270498 | Phase 4 | Mar 14, 2024 | University of Pisa |
| NCT05702970 | Phase 4 | Jan 15, 2024 | University of Padova |
| NCT05989984 | N/A | Aug 4, 2023 | IBSA Institut Biochimique SA, Informapro Srl |
| NCT05678647 | N/A | Jan 31, 2023 | Uppsala University |
| NCT05660200 | N/A | Nov 25, 2022 | IBSA Institut Biochimique SA, Informapro Srl |
| NCT04244058 | Early Phase 1 (Phase 1) | Apr 1, 2020 | Cornell University |
| NCT04587141 | Phase 3 | Jan 1, 2020 | Italian Group for the study of Inflammatory Bowel Disease (IG-IBD), University of Pavia |
| NCT04250298 | Phase 4 | Nov 13, 2019 | Fresenius, Johannes Kepler University, Medical University of Graz |
| NCT05225545 | Phase 3 | Nov 4, 2019 | American University of Beirut, Imerys |
| NCT03560687 | N/A | Jul 1, 2018 | Cardiochirurgia E.H., European Hospital |
| NCT03833336 | Phase 3 | Aug 23, 2017 | Fundació La Marató de TV3, Institut de Recerca Biomèdica de Lleida |
| NCT02916654 | N/A | Apr 1, 2015 | University of Milan |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (20)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cardiochirurgia E.H. | Academic/Hospital | 2 | 2 | 2 | 2018 |
| European Hospital | Academic/Hospital | 2 | 0 | 2 | 2018 |
| IBSA Institut Biochimique SA | For profit | 2 | 2 | 1 | 2022 |
| Informapro Srl | For profit | 2 | 0 | 1 | 2022 |
| American University of Beirut | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Fresenius | For profit | 1 | 0 | 1 | 2019 |
| Fundació La Marató de TV3 | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Imerys | For profit | 1 | 0 | 1 | 2019 |
| Institut de Recerca Biomèdica de Lleida | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Johannes Kepler University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Medical University of Graz | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Pharmanutra s.r.l. | For profit | 1 | 0 | 1 | 2025 |
| University of Milan | Academic/Hospital | 1 | 1 | 1 | 2015 |
| University of Padova | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Pavia | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of Pisa | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Rochester | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Uppsala University | Academic/Hospital | 1 | 1 | 1 | 2023 |
20 organizations
Page 1 / 1